Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2022 annual meeting

Viking Therapeutics, Inc.

Elected Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors; Foehr received 17.1M votes for, Rowland 16.3M.
Ratified Marcum LLP as independent auditor for FY2022 with 50.7M votes for, 0.4M against, 66K abstentions.
Advisory vote on named executive officer compensation passed with 25.2M for, 1.7M against, 0.9M abstain.
Broker non-votes of about 23.4M shares on director elections and say-on-pay due to uninstructed shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.